Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695117 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06695117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06695117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Completed
Start date
November 19, 2024
Completion date
April 16, 2026
Enrollment
980 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 immunization, influenza immunization